|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,010.31 USD | -0.41% |
|
-6.06% | +30.87% |
| 01:46pm | Eli Lilly's Mounjaro added to China's state insurance list for diabetes treatment | RE |
| 08/12 | Lilly's Jaypirca met primary endpoint in head-to-head phase 3 study versus Imbruvica | RE |
| Capitalization | 905B 778B 728B 679B 1,254B 81,414B 1,364B 8,520B 3,290B 38,451B 3,395B 3,323B 140,593B | P/E ratio 2025 * |
44.2x | P/E ratio 2026 * | 31.9x |
|---|---|---|---|---|---|
| Enterprise value | 930B 799B 749B 698B 1,289B 83,657B 1,402B 8,755B 3,381B 39,510B 3,489B 3,414B 144,465B | EV / Sales 2025 * |
14.6x | EV / Sales 2026 * | 12.1x |
| Free-Float |
99.81% | Yield 2025 * |
0.59% | Yield 2026 * | 0.66% |
Last Transcript: Eli Lilly and Company
| 1 day | -0.41% | ||
| 1 week | -6.06% | ||
| Current month | -6.06% | ||
| 1 month | +9.30% | ||
| 3 months | +38.93% | ||
| 6 months | +31.23% | ||
| Current year | +30.87% |
| 1 week | 1,004 |  | 1,068.18 |
| 1 month | 938.4 | | 1,111.99 |
| Current year | 623.78 | | 1,111.99 |
| 1 year | 623.78 | | 1,111.99 |
| 3 years | 302.14 | | 1,111.99 |
| 5 years | 153.68 | | 1,111.99 |
| 10 years | 64.18 | | 1,111.99 |
| Manager | Title | Age | Since |
|---|---|---|---|
David Ricks
CEO | Chief Executive Officer | 57 | 01/01/2017 |
Ruth Gimeno
PSD | President | - | - |
Lucas Montarce
DFI | Director of Finance/CFO | 48 | 09/09/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Jon Fyrwald
BRD | Director/Board Member | 65 | 01/01/2005 |
Ralph Alvarez
BRD | Director/Board Member | 69 | 01/04/2009 |
| Director/Board Member | 53 | 12/12/2011 |
| Name | Weight | AuM | Varia. Jan 1. | Investor |
|---|---|---|---|---|
 | 6.49% | 26 M€ | +11.67% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.41% | -6.06% | +22.21% | +171.61% | 905B | |
| -0.27% | -2.41% | +35.24% | +13.98% | 487B | |
| -1.15% | -0.71% | +28.32% | +36.69% | 400B | |
| +0.26% | +1.14% | +20.97% | +3.22% | 330B | |
| +0.58% | -2.73% | +27.58% | +20.73% | 281B | |
| +0.19% | +2.49% | +19.23% | +24.83% | 255B | |
| -1.16% | -4.87% | -3.27% | -9.42% | 248B | |
| +1.24% | -2.33% | -60.59% | -30.34% | 214B | |
| -3.02% | -4.51% | +21.03% | +15.44% | 178B | |
| -1.14% | -3.67% | +31.57% | +38.08% | 150B | |
| Average | -0.49% | -2.37% | +14.23% | +28.48% | 344.69B | |
| Weighted average by Cap. | -0.40% | -2.83% | +18.23% | +54.99% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 63.55B 54.63B 51.17B 47.7B 88.1B 5,719B 95.82B 599B 231B 2,701B 239B 233B 9,876B | 75.79B 65.15B 61.03B 56.88B 105B 6,821B 114B 714B 276B 3,221B 284B 278B 11,779B |
| Net income | 20.37B 17.51B 16.41B 15.29B 28.24B 1,834B 30.72B 192B 74.1B 866B 76.47B 74.84B 3,166B | 27.83B 23.93B 22.41B 20.89B 38.59B 2,505B 41.97B 262B 101B 1,183B 104B 102B 4,326B |
| Net Debt | 24.92B 21.42B 20.07B 18.7B 34.54B 2,243B 37.57B 235B 90.62B 1,059B 93.52B 91.53B 3,873B | 8.75B 7.52B 7.05B 6.57B 12.13B 788B 13.2B 82.43B 31.83B 372B 32.85B 32.15B 1,360B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 05/12/25 | 1,010.31 $ | -0.41% | 2,502,066 |
| 04/12/25 | 1,014.49 $ | -1.85% | 3,854,911 |
| 03/12/25 | 1,033.56 $ | -1.20% | 3,447,003 |
| 02/12/25 | 1,046.12 $ | -1.11% | 3,279,960 |
| 01/12/25 | 1,057.89 $ | -1.63% | 3,070,153 |
Delayed Quote Nyse, 06 December 2025 at 08:00 am AEDT
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- LLY Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition